What stage does NGN Capital invest at?

NGN Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.

What sectors does NGN Capital focus on?

NGN Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is NGN Capital located?

NGN Capital is headquartered in New York, US.

NGN Capital

Venture capital

New York · Series A–Late Stage · 6 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

NGN Capital is a venture capital firm dedicated to the healthcare sector, backing companies across biotech, pharmaceutical, and medical device fields. The team combines deep industry, clinical, and financial experience, drawing on backgrounds in pharmaceutical development, healthcare investment banking, corporate development, and drug and device approvals. Operating from New York and Heidelberg, Germany, the firm invests through U.S. and German funds totaling roughly $450 million.

Invests inBiotech Digital Health Healthtech Medical DevicesEuropeGermanyIsraelNew YorkNorth AmericaStamfordSwitzerlandUnited States

Source: firm website, verified Aug 11, 2026.

Stage

Series A–Late Stage

New York, Connecticut, US

Instruments

Equity

Founded

2004

AUM

$450M

VC funds

Tracked investments

Team · 6 people

from the firm's website & public directories

Kenneth Abramowitz· Co-Founder and Managing General Partner

Kenneth S. Abramowitz co-founded NGN Capital and serves as a Managing General Partner. He previously was a Managing Director and later Senior Advisor at The Carlyle Group in New York (2001-2003), where he focused on U.S. healthcare buyouts, and spent 23 years as an analyst at Sanford C. Bernstein & Co. covering the medical-supply, hospital-management, and HMO industries, followed by a role as a healthcare fund manager at EGS Securities. He holds a B.A. from Columbia University and an M.B.A. from Harvard Business School.

k•••@ngncapital.comreveal

Kenneth J. Gorelick· Venture Partner

A physician with three decades of experience developing drugs, biologics, and medical devices. He has held senior clinical development roles at Dupont Merck and Genelabs and serves as a consultant to the biopharmaceutical industry.

William J. Gedale· Senior Advisor

Senior Advisor and co-founder of NGN Capital with an investment career dating to 1965. He founded Mount Everest Advisors, consulted for Warburg-Pincus, and led General American Investors as President and CEO.

Alexander Cuomo· Chief Financial Officer

CFO of NGN Capital since 2008, responsible for financial reporting, tax and audit compliance, portfolio valuation, budgeting, and investor relations across the U.S. and German funds. He holds a master's in finance from Pace University.

a•••@ngncapital.comreveal

John Costantino· Senior Advisor (formerly Managing General Partner)· New York City

John R. Costantino is a Senior Advisor to and former Managing General Partner of NGN Capital, a group of healthcare-focused venture funds. A lawyer and CPA, he previously served as Managing Tax Partner in the New York office of Touché Ross & Co., President of Integrated Resources Acquisition Corporation, and Chief Operating Officer of Conair Corporation, and was a founding partner of a private equity fund and merchant banking group as well as a co-founder of several biotech and medical device companies.

j•••@ngncapital.comreveal

Peter Johann· Managing General Partner

Managing General Partner at NGN Capital with a background in biotech and pharmaceutical business development, having previously held senior corporate development, licensing, and marketing roles at Boehringer Ingelheim, F. Hoffmann-La Roche, and Boehringer Mannheim. He holds a Ph.D. from the Technical University Munich and serves on several life sciences company boards including Exosome Diagnostics and Vivaldi Biosciences.

p•••@ngncapital.comreveal

What they invest in

from 1 of 1 portfolio companies

Biotech ×1

HQs:United States×1

Investments · 1 tracked

founders shown can be your intro path

NeurotropeNov 2016SEC filingmedium confidence

BiotechNewark, US

Robert Weinstein(Executive Officer)Larry D. Altstiel, MD(Director)William Singer(Vice Chairman of the Board)Charles S. Ramat(Executive Officer, Director)Paul E. Freiman(Chairman of the Board)Jay M. Haft(Director)

Board seatKenneth J. Gorelick· per SEC Form D · $24.5M raise · filed Dec 2016

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Fund performance · per public LP disclosures · 2

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
NGN BioMed Opportunity IILPs: New York City Police Pension Fund	2008	—	0.6%	1.05x	1.05x
NGN BioMed Opportunity II, L.P.LPs: New York City Employees' Retirement System, Teachers' Retirement System of the City of New York, New York City Police Pension Fund +1 more	2008	—	0.6%	1.05x	1.05x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

What stage does NGN Capital invest at?: NGN Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does NGN Capital focus on?: NGN Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is NGN Capital located?: NGN Capital is headquartered in New York, US.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.

$50K – $12.7M

Capricorn Venture Partners

Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.

$270K – $10.8M

Novartis Venture Fund

The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.

$5M – $25M

Pontifax Venture Capital

Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.

$6.3M – $128M

EQT Life Sciences

EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.

$11M – $66M